Kamada Ltd. (NASDAQ:KMDA) – Stock analysts at Jefferies Group dropped their FY2020 earnings estimates for shares of Kamada in a research report issued on Tuesday, May 15th. Jefferies Group analyst R. Denhoy now anticipates that the biotechnology company will earn $0.61 per share for the year, down from their previous forecast of $0.62. Jefferies Group also issued estimates for Kamada’s FY2021 earnings at $0.36 EPS.
Get Kamada alerts:
KMDA has been the topic of several other reports. ValuEngine lowered shares of Kamada from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Friday, February 9th. Chardan Capital began coverage on shares of Kamada in a research note on Friday, February 2nd. They set a “buy” rating and a $7.00 target price on the stock. HC Wainwright reissued a “buy” rating on shares of Kamada in a research note on Thursday, February 8th. Finally, TheStreet raised shares of Kamada from a “c” rating to a “b” rating in a research note on Friday, February 9th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $6.50.
Shares of NASDAQ KMDA opened at $4.90 on Friday. The firm has a market cap of $195.27 million, a P/E ratio of 27.22 and a beta of 1.17. Kamada has a 12-month low of $3.75 and a 12-month high of $8.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.58 and a current ratio of 3.47.
Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported $0.03 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.03. Kamada had a net margin of 11.17% and a return on equity of 14.64%. The company had revenue of $17.44 million during the quarter, compared to analysts’ expectations of $24.89 million.
An institutional investor recently bought a new position in Kamada stock. ARK Investment Management LLC bought a new position in shares of Kamada Ltd. (NASDAQ:KMDA) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 52,695 shares of the biotechnology company’s stock, valued at approximately $251,000. ARK Investment Management LLC owned approximately 0.13% of Kamada as of its most recent SEC filing. 9.42% of the stock is currently owned by institutional investors.
Kamada Company Profile
Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin deficiency (AATD).